• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Viatris Named to Forbes' World's Top Companies for Women 2024 List

    10/29/24 12:00:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email

    PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.

    "At Viatris, diverse perspectives drive innovation and our ability to make an impact, as we empower people worldwide to live healthier at every stage of life," said Andrew Enrietti, Chief People Officer, Viatris. "Being recognized on Forbes' list of the World's Top Companies for Women 2024 demonstrates our focus on investing in our people and fostering diverse talent. This accolade is a true testament to the continued progress we are making in growing and supporting our female talent and the inclusive culture we are building at Viatris."

    The World's Top Companies for Women 2024 were chosen among multi-national corporations that were evaluated in multiple globally administered independent surveys of approximately 100,000 women in 37 countries. Over 750,000 data points were collected. The final analysis is based on:

    • Employer Brand Score: Women were asked to rate how their employer performs across a series of gender-related topics and their overall willingness to recommend their employer, as well as evaluate other employers in their respective industries.
    • Public Opinion Score: A women-only public opinion survey measured how women perceive companies in terms of gender equality.
    • Leadership Score: Objective criteria (i.e., the presence of a female CEO and the share of board/executive committee positions filled by women) were gathered.

    "At Viatris, we embrace every colleague's unique experiences, perspectives and skills and are committed to ensuring women are at the table when important decisions are made, including those that affect other women and their access to high-quality healthcare," said Lara Ramsburg, Chief Corporate Affairs Officer, Viatris, and Executive Sponsor of EmpoWer, Viatris' women's Employee Resource Group. "This award is a recognition of this collective effort as well as a testament to the dedication and impact of the membership of EmpoWer, which has grown exponentially since its formation and aims to collaboratively drive an ecosystem within Viatris that empowers women to reach their full potential."

    To learn more about Viatris' performance-driven, highly engaging and inclusive culture, please visit its careers site as well as on the Company's ERG page, which are the groups where we bring together colleagues and allies with a shared focus on raising awareness of the unique lived experiences of different communities. 

    Being named to Forbes' list of World's Top Companies for Women 2024 follows Viatris' inclusion on Forbes' World's Best Employers 2024 list, TIME's World's Most Sustainable Companies 2024 list and USA Today's list of America's Climate Leaders 2024. The Company has also received Great Place to Work® certifications and Top Employers certifications in multiple countries, among others.

    About Viatris

    Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).

    Viatris OUS Logo (PRNewsfoto/Viatris Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-named-to-forbes-worlds-top-companies-for-women-2024-list-302290273.html

    SOURCE Viatris Inc.

    Get the next $VTRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What recognition has Viatris Inc. recently achieved?

      Viatris Inc. has been recognized in the 2024 Forbes list of Top Companies for Women, emphasizing its commitment to gender equality in the workplace.

    • How were the companies selected for the Forbes list of Top Companies for Women?

      The award is derived from comprehensive surveys of approximately 100,000 women across 37 countries, which assess companies based on employer brand, public opinion, and leadership diversity.

    • What does Viatris attribute to its recognition on the Forbes list?

      Andrew Enrietti, Chief People Officer at Viatris, highlighted that diverse perspectives fuel innovation and that the company actively supports female talent.

    • What other recognitions has Viatris received that reflect its corporate culture?

      This recognition aligns with Viatris' previous awards, including Forbes' Best Employers, TIME's Most Sustainable Companies, and USA Today's Climate Leaders, showcasing its broader commitment to corporate responsibility.

    • How does Viatris plan to support women beyond its internal initiatives?

      Viatris aims to empower women not only within the organization but also in shaping healthcare policies affecting women, as stated by Lara Ramsburg, Chief Corporate Affairs Officer.

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    2/9/2026$18.00Neutral → Buy
    UBS
    1/16/2026$15.00Hold → Buy
    Argus
    12/9/2025$15.00Overweight
    Barclays
    10/15/2025$15.00Buy
    Truist
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Campbell Paul

    4 - Viatris Inc (0001792044) (Issuer)

    3/24/26 6:04:35 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Viatris Inc.

    4 - Viatris Inc (0001792044) (Issuer)

    3/10/26 7:03:54 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kilts James M converted options into 24,835 shares, increasing direct ownership by 18% to 161,257 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    3/10/26 7:03:50 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Viatris Inc.

    DEFA14A - Viatris Inc (0001792044) (Filer)

    4/2/26 4:31:39 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Viatris Inc.

    DEF 14A - Viatris Inc (0001792044) (Filer)

    4/2/26 4:30:52 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.

    SCHEDULE 13G/A - Viatris Inc (0001792044) (Subject)

    3/27/26 1:54:06 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

    PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the

    4/13/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

    PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026.The presentations will include data across various areas of ophthalmology, including full results from VEGA-3, a Phase 3 study evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia; results from a Phase 1 study of varenicline solution nasal spray in healthy Japanese adults; and a post-hoc analysis of MIRA-2, a Phase 3 study evaluating the optical impact of RYZUMVI® for reversing pharmacologically-induc

    4/10/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

    Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GADPITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor (SNRI), for the treatment of adults with generalized anxiety disorder (GAD). Following the MHLW's decision, Effexor® becomes the first and only approved treatment option in Japan for adults living with GAD, addressing a long-standing unmet medical need in mental health and enabling new access to care. Eff

    3/23/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Viatris upgraded by UBS with a new price target

    UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00

    2/9/26 6:59:24 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris upgraded by Argus with a new price target

    Argus upgraded Viatris from Hold to Buy and set a new price target of $15.00

    1/16/26 8:41:55 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Viatris with a new price target

    Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:55:06 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Leadership Updates

    Live Leadership Updates

    View All

    Viatris Appoints Matthew J. Maletta as Chief Legal Officer

    Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition

    2/3/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

    PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies. Ramsburg is an accomplished leader with more than 25 years of experience building and leading highly effective cross-functional

    1/8/26 9:05:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

    PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.

    8/19/25 9:00:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Smith Scott Andrew bought $219,740 worth of shares (22,000 units at $9.99), increasing direct ownership by 8% to 314,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    8/13/25 6:08:30 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    5/14/25 6:00:11 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    10/25/24 4:30:03 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viatris Inc.

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    11/12/24 1:41:20 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    2/13/24 5:17:31 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Viatris Inc.

    SC 13G - Viatris Inc (0001792044) (Subject)

    2/9/24 1:10:51 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Financials

    Live finance-specific insights

    View All

    Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

    PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the

    4/13/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All Key Metrics[1]Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026Provides 2026 Financial Guidance; Positioned for Sustainable GrowthAnticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline MilestonesCompletes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 YearsPITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced robust financial results for the four

    2/26/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

    PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2026, to shareholders of record as of the close of business on March 9, 2026. This marks the sixth consecutive year the Company has paid a dividend.                 About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of bo

    2/26/26 6:55:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care